STAT+: Former FDA commissioners Califf, Gottlieb, Sharpless lay into current HHS leadership

Robert Califf is a physician and researcher who served as FDA commissioner from 2016 to 2017 and again from 2022 to 2025. His work emphasized medical evidence, clinical research, and the agency’s review of drugs and medical products. Scott Gottlieb served from 2017 to 2019. He pursued faster generic-drug competition, addressed opioid risks, and promoted new approaches to tobacco and digital-health regulation.

Robert Sharpless was acting FDA commissioner from 2019 to 2019, after Gottlieb left and before Stephen Hahn became commissioner. He kept the agency operating during the leadership transition and brought experience in cancer research and drug development. An acting commissioner has the same operational responsibility but usually serves temporarily.

The supplied excerpt does not describe these commissioners or their actions. Their records matter because FDA commissioners balance scientific standards, public safety, innovation, and political pressure while overseeing decisions affecting patients, manufacturers, and consumers.

The supplied excerpt contains no discussion of Robert Califf, Scott Gottlieb, Robert Sharpless, or criticism of current HHS leadership. It mentions that Rep. Jake Auchincloss would discuss stabilizing the FDA, but it does not report former commissioners’ statements or identify the leadership decisions they challenged.

Because the specific criticism is absent, assigning one would risk confusing background knowledge with the source. Former FDA commissioners have often defended scientific independence, evidence-based review, and stable agency leadership. Those are broad themes, not a documented answer to this question from the supplied text.

The safest conclusion is that the excerpt does not provide enough information to identify the criticism. A complete answer would require the missing passage or the former commissioners’ actual remarks. Without that material, no precise claim about their objections should be presented as an article fact.

The Food and Drug Administration, or FDA, is a federal public-health agency. It evaluates and regulates products that can affect health, including prescription and over-the-counter medicines, biologics, vaccines, medical devices, food, cosmetics, tobacco products, and some radiation-emitting equipment. Its purpose is to reduce preventable harm while allowing useful products to reach the public.

For medicines, the FDA reviews evidence about benefits, risks, manufacturing quality, and labeling before approval. It also monitors safety after products reach the market. For food, it addresses contamination, harmful ingredients, labeling, and manufacturing practices. For devices, it evaluates safety and performance according to the product’s risk.

The supplied excerpt does not define the FDA or list its responsibilities. These descriptions come from established U.S. government background. The FDA does not regulate every health-related product; agencies such as USDA and EPA oversee important areas outside its jurisdiction.

The Department of Health and Human Services, or HHS, is a cabinet-level department responsible for protecting public health and administering major health programs. It includes agencies such as the FDA, CDC, NIH, and CMS. HHS sets broad departmental priorities, manages budgets, and provides administrative oversight.

The FDA is one operating component inside HHS. It has specialized scientific and regulatory responsibilities, including reviewing medicines, monitoring food safety, and overseeing medical devices. The HHS secretary is above the FDA commissioner in the department’s organizational structure, while the commissioner manages the FDA’s daily work.

The supplied excerpt does not explain HHS or the FDA’s organizational relationship. This description uses established federal-government information. The relationship matters because HHS leadership can influence priorities and resources, while credible FDA decisions depend on professional expertise, transparent evidence, and consistent regulatory processes.

The FDA’s assignment is unusually broad. It oversees about 80% of the U.S. food supply, with the USDA handling key categories such as meat, poultry, and processed egg products. The FDA also regulates prescription drugs, most over-the-counter medicines, biologics, medical devices, cosmetics, tobacco products, and some radiation-emitting products.

For medicines, a simple percentage can mislead. The FDA is the principal federal regulator for drugs marketed in the United States, but products differ by category, and some compounded or otherwise specialized products follow different rules. The agency also shares public-health responsibilities with other federal and state bodies.

The supplied excerpt does not give these figures or describe the FDA’s scope. The 80% estimate is widely used in official FDA descriptions, while the medicines explanation reflects the agency’s established jurisdiction. Its scale explains why leadership stability can affect food, medicine, and health policy nationwide.

The FDA depends on clear authority, scientific staff, reliable funding, and cooperation with HHS leadership. If that relationship breaks down, decisions may take longer or become inconsistent. Manufacturers could face uncertainty, while patients and consumers could wait longer for needed products or warnings.

For example, a delayed review could postpone approval of a useful medicine. Weak coordination could also slow inspections, recalls, or responses to contaminated food. During an infectious-disease emergency, disagreements could hinder communication about tests, vaccines, treatments, or changing risks. These outcomes are possible consequences of institutional failure, not events reported in the supplied excerpt.

The excerpt specifically says Rep. Jake Auchincloss would discuss how to stabilize the FDA. It does not report an actual breakdown or quantify any effects. The forward implication is that stable leadership and coordinated oversight are important for timely approvals, food protection, and credible public-health action.

An independent, science-based regulator asks whether reliable evidence shows that a medicine or device works and whether its risks are understood and manageable. Political leaders may set broad priorities, but technical decisions require trained reviewers, transparent standards, and consistent procedures. This protects people who cannot personally verify complex safety data.

For example, FDA reviewers can examine clinical-trial results, manufacturing controls, warnings, and reported side effects before and after approval. A product may be promising, but evidence can reveal ineffective treatment, unexpected harm, contamination, or unreliable production. Independent review gives those findings greater credibility.

The supplied excerpt does not discuss regulatory independence directly. The principle comes from established public-health practice. It matters because rushed or politically driven decisions can expose patients to harm, while excessive delay can block beneficial treatments. Strong regulators must manage both risks using evidence and public accountability.